“Our team remains focused on advancing PALI-2108 towards our first-in-human study, which is on track to start later this year. Our growing body of data, including the most recent data from two ex-vivo studies evaluating PALI-2108, coupled with our strategic partnership with Strand Life Sciences, further build our confidence in the robust anti-inflammatory potential of PALI-2108 in the treatment of UC. Most importantly, the data underscore its potential as a next-generation therapeutic option for patients with inflammatory bowel disease,” commented J.D. Finley, Chief Executive Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Palisade Bio Welcomes New Board Member, Eyes Strategic Growth
- Palisade Bio appoints Fischbein to board of directors
- Palisade Bio Appoints Margery Fischbein to its Board of Directors
- Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules